A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
作者信息
Pal Sumanta Kumar, Vogelzang Nicholas J
机构信息
Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
出版信息
Clin Genitourin Cancer. 2013 Mar;11(1):1-4. doi: 10.1016/j.clgc.2012.11.006. Epub 2012 Dec 29.
Abstract
摘要
相似文献
1
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Clin Genitourin Cancer. 2013 Mar;11(1):1-4. doi: 10.1016/j.clgc.2012.11.006. Epub 2012 Dec 29.
2
Signaling inhibitors in metastatic renal cell carcinoma.
Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.
3
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
4
[Novelties in the treatment for advanced renal-cell cancer].
Orv Hetil. 2011 Apr 24;152(17):655-62. doi: 10.1556/OH.2011.29100.
5
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8.
6
[Medical treatment of renal cell carcinoma].
Prog Urol. 2013 Nov;23(15):1225-37. doi: 10.1016/j.purol.2013.09.011. Epub 2013 Oct 21.
7
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Am J Clin Oncol. 2014 Dec;37(6):611-5. doi: 10.1097/COC.0b013e31827de888.
8
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.
9
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
J BUON. 2007 Sep;12 Suppl 1:S151-62.
10
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.
引用本文的文献
1
Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
Curr Oncol Rep. 2018 Apr 2;20(5):41. doi: 10.1007/s11912-018-0684-z.
2
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Am Soc Clin Oncol Educ Book. 2017;37:319-329. doi: 10.1200/EDBK_174469.
本文引用的文献
1
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ann Oncol. 2015 Jul;26(7):1378-84. doi: 10.1093/annonc/mdv170. Epub 2015 Apr 7.
2
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Curr Med Res Opin. 2014 Oct;30(10):2041-50. doi: 10.1185/03007995.2014.938730. Epub 2014 Jul 9.
3
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
J Clin Oncol. 2014 Mar 10;32(8):752-9. doi: 10.1200/JCO.2013.50.5305. Epub 2013 Dec 2.
4
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9.
5
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
Cancer Discov. 2012 Mar;2(3):270-87. doi: 10.1158/2159-8290.CD-11-0240. Epub 2012 Feb 24.
6
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.
7
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Clin Cancer Res. 2011 Nov 15;17(22):7156-63. doi: 10.1158/1078-0432.CCR-11-0411. Epub 2011 Oct 5.
8
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12.
9
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.
Mol Cancer Ther. 2010 Dec;9(12):3115-25. doi: 10.1158/1535-7163.MCT-10-0873. Epub 2010 Nov 15.
10
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.
Zotero 插件